Free Trial

Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Increases By 28.4%

DiaMedica Therapeutics logo with Medical background

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 1,100,000 shares, a growth of 28.4% from the May 15th total of 856,900 shares. Approximately 2.8% of the company's stock are short sold. Based on an average daily volume of 99,000 shares, the short-interest ratio is currently 11.1 days.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Paragon Associates & Paragon Associates II Joint Venture boosted its stake in DiaMedica Therapeutics by 6.7% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company's stock worth $2,795,000 after purchasing an additional 32,170 shares in the last quarter. Susquehanna International Group LLP boosted its stake in DiaMedica Therapeutics by 269.5% in the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after purchasing an additional 273,395 shares in the last quarter. Northern Trust Corp boosted its stake in DiaMedica Therapeutics by 49.8% in the 4th quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after purchasing an additional 59,902 shares in the last quarter. Royal Bank of Canada boosted its stake in DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock worth $588,000 after purchasing an additional 154,701 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in DiaMedica Therapeutics by 8.2% in the 4th quarter. LPL Financial LLC now owns 152,000 shares of the company's stock worth $825,000 after purchasing an additional 11,500 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Trading Down 5.5%

Shares of NASDAQ:DMAC traded down $0.21 during trading on Friday, reaching $3.61. The stock had a trading volume of 174,275 shares, compared to its average volume of 87,236. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.82. The company has a market capitalization of $154.80 million, a P/E ratio of -5.64 and a beta of 1.23. The firm's 50-day simple moving average is $3.96 and its 200 day simple moving average is $4.90.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). During the same quarter in the prior year, the firm earned ($0.14) earnings per share. Equities research analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of DiaMedica Therapeutics in a research report on Thursday, May 29th.

Read Our Latest Stock Report on DMAC

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

Read More

Should You Invest $1,000 in DiaMedica Therapeutics Right Now?

Before you consider DiaMedica Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.

While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines